

FOR IMMEDIATE RELEASE

Zurich, Switzerland – November 29, 2007

## Dualsystems Biotech completes CHF 2.2M financing round

**Dualsystems Biotech AG**, a Zurich-based biotechnology company marketing custom services and products for the Functional Proteomics market has announced today that it has successfully completed its CHF 2.2M financing round. Investors include existing shareholders, private investors and the Zürcher Kantonalbank.

The financing round strengthens the position of Dualsystems in the Functional Proteomics market by extending both the product and services portfolio and by significantly increasing Marketing & Sales activities. In addition, Dualsystems will apply its existing technology platforms in the emerging area of drug repositioning, where a significant unmet need exists. Dr. Daniel Auerbach, Chief Executive Officer, comments: "We feel that broadening our existing activities as well as investing into new markets significantly increases the attractiveness of Dualsystems as a global proteomics solutions provider."

Dualsystems Biotech was founded in 2000 and is a major supplier of custom services and products to the academic and industry Life Sciences market. Over the past six years, the company has brought to the market several assays for the identification and characterization of protein interactions *in vivo* and also holds significant intellectual property in this area.

For additional information please contact:

Dualsystems Biotech AG  
Dr. Daniel Auerbach, CEO  
Grabenstrasse 11a  
8952 Schlieren, Switzerland

phone +41 44 738 50 00  
fax +41 44 738 50 05  
info@dualsystems.com

*This press release contains forward-looking statements, which are subject to risks and uncertainties inherent to the process of developing and commercializing products and services. Actual results may differ materially from those projected in this release.*